Cambrex Corporation (NYSE:CBM) – Equities researchers at First Analysis reduced their Q4 2017 earnings per share (EPS) estimates for shares of Cambrex Corporation in a research note issued on Monday. First Analysis analyst S. Schwartz now forecasts that the biotechnology company will post earnings per share of $1.11 for the quarter, down from their previous estimate of $1.18. First Analysis also issued estimates for Cambrex Corporation’s Q1 2018 earnings at $0.47 EPS, Q3 2018 earnings at $0.56 EPS and FY2018 earnings at $2.90 EPS.
Several other brokerages also recently weighed in on CBM. BidaskClub downgraded Cambrex Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. ValuEngine upgraded Cambrex Corporation from a “hold” rating to a “buy” rating in a research note on Tuesday, August 22nd. Finally, Craig Hallum restated a “buy” rating and set a $60.00 target price (down from $70.00) on shares of Cambrex Corporation in a research note on Tuesday, October 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $62.33.
TRADEMARK VIOLATION WARNING: “Q4 2017 Earnings Forecast for Cambrex Corporation (CBM) Issued By First Analysis” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/11/17/q4-2017-earnings-forecast-for-cambrex-corporation-cbm-issued-by-first-analysis.html.
Shares of Cambrex Corporation (NYSE CBM) traded up $0.95 during mid-day trading on Wednesday, reaching $48.30. The company had a trading volume of 770,900 shares, compared to its average volume of 335,209. Cambrex Corporation has a 1 year low of $42.55 and a 1 year high of $62.95. The stock has a market cap of $1,552.02, a P/E ratio of 14.94 and a beta of 2.26.
Cambrex Corporation (NYSE:CBM) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.47 by $0.08. Cambrex Corporation had a return on equity of 23.42% and a net margin of 18.79%. The firm had revenue of $112.60 million during the quarter, compared to analyst estimates of $108.44 million. During the same period in the previous year, the company posted $0.47 EPS. The business’s revenue for the quarter was up 13.4% compared to the same quarter last year.
In other Cambrex Corporation news, CEO Steven M. Klosk sold 12,000 shares of the business’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $51.53, for a total transaction of $618,360.00. Following the sale, the chief executive officer now owns 95,328 shares in the company, valued at approximately $4,912,251.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Steven M. Klosk sold 4,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $54.96, for a total value of $219,840.00. Following the sale, the chief executive officer now owns 87,328 shares in the company, valued at approximately $4,799,546.88. The disclosure for this sale can be found here. 2.48% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of CBM. Vanguard Group Inc. boosted its stake in shares of Cambrex Corporation by 4.6% in the first quarter. Vanguard Group Inc. now owns 3,138,934 shares of the biotechnology company’s stock worth $172,799,000 after buying an additional 139,010 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Cambrex Corporation by 12.5% in the first quarter. Geode Capital Management LLC now owns 281,913 shares of the biotechnology company’s stock worth $15,518,000 after buying an additional 31,250 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Cambrex Corporation in the first quarter worth about $10,559,000. Schwab Charles Investment Management Inc. boosted its stake in shares of Cambrex Corporation by 20.9% in the first quarter. Schwab Charles Investment Management Inc. now owns 145,527 shares of the biotechnology company’s stock worth $8,012,000 after buying an additional 25,129 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Cambrex Corporation by 7.6% in the first quarter. State Street Corp now owns 742,151 shares of the biotechnology company’s stock worth $40,858,000 after buying an additional 52,638 shares during the last quarter.
About Cambrex Corporation
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.